JP2018527360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527360A5 JP2018527360A5 JP2018512334A JP2018512334A JP2018527360A5 JP 2018527360 A5 JP2018527360 A5 JP 2018527360A5 JP 2018512334 A JP2018512334 A JP 2018512334A JP 2018512334 A JP2018512334 A JP 2018512334A JP 2018527360 A5 JP2018527360 A5 JP 2018527360A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- compound according
- protein
- compound
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222059P | 2015-09-22 | 2015-09-22 | |
| US62/222,059 | 2015-09-22 | ||
| PCT/US2016/052829 WO2017053391A1 (en) | 2015-09-22 | 2016-09-21 | Modified cytotoxins and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527360A JP2018527360A (ja) | 2018-09-20 |
| JP2018527360A5 true JP2018527360A5 (enExample) | 2019-10-31 |
Family
ID=58276138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512334A Pending JP2018527360A (ja) | 2015-09-22 | 2016-09-21 | 修飾された細胞毒とその治療的使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10023581B2 (enExample) |
| EP (1) | EP3353159A4 (enExample) |
| JP (1) | JP2018527360A (enExample) |
| KR (1) | KR20180045001A (enExample) |
| CN (1) | CN108368075A (enExample) |
| AU (1) | AU2016326392B2 (enExample) |
| CA (1) | CA2998528A1 (enExample) |
| HK (1) | HK1254461A1 (enExample) |
| IL (1) | IL257932A (enExample) |
| MX (1) | MX380314B (enExample) |
| MY (1) | MY193776A (enExample) |
| RU (1) | RU2721949C2 (enExample) |
| WO (1) | WO2017053391A1 (enExample) |
| ZA (1) | ZA201801482B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017053391A1 (en) * | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| CN110636865A (zh) * | 2017-03-22 | 2019-12-31 | 加利福尼亚大学董事会 | 修饰的寡核苷酸及其治疗用途 |
| US20220273607A1 (en) * | 2019-07-09 | 2022-09-01 | Northwestern University | Methods of using modified cytotoxins to treat cancer |
| IT202100025172A1 (it) | 2021-09-30 | 2023-03-30 | Indena Spa | Processo per la preparazione di derivati tassanici |
| KR20250057244A (ko) | 2023-10-20 | 2025-04-29 | (주)블루엔씨 | 고정밀 3d 프린팅 기반 금형 제작 방법 및 장치 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411984A (en) | 1992-10-16 | 1995-05-02 | Virginia Tech Intellectual Properties, Inc. | Water soluble analogs and prodrugs of taxol |
| WO1994029327A1 (en) * | 1993-06-07 | 1994-12-22 | British Technology Group Limited | Anticancer compounds |
| US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| AU735205B2 (en) | 1997-05-16 | 2001-07-05 | Commonwealth Scientific And Industrial Research Organisation | Vaccine and assay |
| US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| AU2002953095A0 (en) * | 2002-11-29 | 2002-12-19 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| NO319551B1 (no) | 2003-07-04 | 2005-08-29 | Thia Medica As | Proteinmateriale fra enkeltceller |
| GB0321613D0 (en) | 2003-09-15 | 2003-10-15 | Drug Discovery Lab As | Compounds |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| RU2340616C2 (ru) * | 2003-10-29 | 2008-12-10 | Сонус Фармасьютикалз, Инк. | Токоферол-модифицированные терапевтические лекарственные соединения |
| GB0412181D0 (en) * | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| WO2006030217A2 (en) * | 2004-09-15 | 2006-03-23 | Drug Discovery Laboratory As | Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs |
| JP5755398B2 (ja) | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー／エス | 伸長されたｇｌｐ−１化合物 |
| TW200731991A (en) * | 2005-12-20 | 2007-09-01 | Sonus Pharma Inc | Lipophilic di(anticancer drug) compounds, compositions and related methods |
| CN104474529A (zh) | 2008-02-08 | 2015-04-01 | 爱勒让治疗公司 | 治疗性的拟肽大环化合物 |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| WO2010107487A2 (en) | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
| KR20110134510A (ko) | 2009-04-02 | 2011-12-14 | 샤이어 엘엘씨 | 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도 |
| JP2013516471A (ja) | 2010-01-06 | 2013-05-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 薬物の脂肪酸誘導体および類似体 |
| RU2605627C2 (ru) | 2010-01-22 | 2016-12-27 | Ново Нордиск Хелс Кеа Аг | Гормоны роста с пролонгированной эффективностью in vivo |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| ES2582590T3 (es) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Método de purificación |
| CA2800497C (en) * | 2010-05-10 | 2019-03-12 | The Regents Of The University Of California | Methods for preparing ratiometric combinatorial nanoparticules |
| EP2392324A1 (en) * | 2010-06-01 | 2011-12-07 | Societe De Coordination De Recherches Therapeutiques | Rhenium complexes and their pharmaceutical use |
| EA201390450A1 (ru) | 2010-09-28 | 2013-07-30 | Амилин Фармасьютикалс, Ллк. | Полипептиды с увеличенной продолжительностью действия |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| EP2624869A4 (en) * | 2010-10-08 | 2015-11-04 | Univ Virginia Commonwealth | PRODRUGS USING A CONTAINER CONTROLLED ABSORPTION MECHANISM |
| EP2723452A2 (en) | 2011-06-22 | 2014-04-30 | Vyome Biosciences Pvt Ltd | Conjugate-based antifungal and antibacterial prodrugs |
| ES2732475T3 (es) | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| KR101435261B1 (ko) * | 2012-07-23 | 2014-09-02 | 아주대학교산학협력단 | 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물 |
| AU2013350311B2 (en) * | 2012-11-21 | 2018-03-22 | The University Of Sydney | Omega-3 analogues |
| US9962452B2 (en) * | 2013-02-04 | 2018-05-08 | Zhuhai Beihai Biotech Co., Ltd. | Soluble complexes of drug analogs and albumin |
| US20160115192A1 (en) * | 2013-06-10 | 2016-04-28 | Cedars-Sinai Medical Center | Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof |
| CN112043835B (zh) | 2013-12-06 | 2022-10-21 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| SI3750545T1 (sl) * | 2014-11-17 | 2024-06-28 | Cellectar Biosciences, Inc. | Analogi fosfolipidnega etra kot nosilci zdravil, ki ciljajo na raka |
| CN104478813A (zh) * | 2014-12-20 | 2015-04-01 | 苏州博源医疗科技有限公司 | 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒 |
| US10286079B2 (en) * | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| WO2017053391A1 (en) * | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| US20210137874A1 (en) * | 2017-03-22 | 2021-05-13 | The Regents Of The University Of California | Modified platinum compounds and therapeutic uses thereof |
| US20200048198A1 (en) * | 2017-03-22 | 2020-02-13 | The Regents Of The University Of California | Modified histone deacetylase inhibitors and uses thereof |
| WO2018175622A1 (en) * | 2017-03-22 | 2018-09-27 | The Regents Of The University Of California | Modified anthracycline compounds and their therapeutic use |
| SG11201908911QA (en) * | 2017-04-27 | 2019-11-28 | Univ California | Modified mri contrast agents and uses thereof |
-
2016
- 2016-09-21 WO PCT/US2016/052829 patent/WO2017053391A1/en not_active Ceased
- 2016-09-21 CN CN201680054455.9A patent/CN108368075A/zh active Pending
- 2016-09-21 RU RU2018107843A patent/RU2721949C2/ru active
- 2016-09-21 AU AU2016326392A patent/AU2016326392B2/en not_active Expired - Fee Related
- 2016-09-21 US US15/271,822 patent/US10023581B2/en active Active
- 2016-09-21 HK HK18113547.1A patent/HK1254461A1/zh unknown
- 2016-09-21 CA CA2998528A patent/CA2998528A1/en not_active Abandoned
- 2016-09-21 MY MYPI2018000369A patent/MY193776A/en unknown
- 2016-09-21 KR KR1020187008860A patent/KR20180045001A/ko not_active Withdrawn
- 2016-09-21 MX MX2018002514A patent/MX380314B/es unknown
- 2016-09-21 EP EP16849481.3A patent/EP3353159A4/en not_active Withdrawn
- 2016-09-21 JP JP2018512334A patent/JP2018527360A/ja active Pending
-
2018
- 2018-03-02 ZA ZA2018/01482A patent/ZA201801482B/en unknown
- 2018-03-06 IL IL257932A patent/IL257932A/en unknown
- 2018-04-04 US US15/945,285 patent/US10654864B2/en active Active - Reinstated
-
2020
- 2020-04-09 US US16/844,627 patent/US20210047338A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003102A (es) | Degradadores bifuncionales de brd9 y sus metodos de uso. | |
| JP2016506916A5 (enExample) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| JP2017518302A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| RU2021103727A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| JP2016539134A5 (enExample) | ||
| JP2016532710A (ja) | 免疫調節剤としての１，２，４−オキサジアゾール誘導体 | |
| EP4410317A3 (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| JP2016532711A (ja) | 免疫調節剤としての１，３，４−オキサジアゾール及び１，３，４−チアジアゾールの誘導体 | |
| JP2019504100A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2017531619A5 (enExample) | ||
| CL2014000363A1 (es) | Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros. | |
| JP2019521180A5 (enExample) | ||
| JP2017536344A5 (enExample) | ||
| JP2008200039A5 (enExample) | ||
| CN104530417A (zh) | 一种多官能化h型聚乙二醇衍生物及其制备方法 | |
| EP4275748A3 (en) | Compositions and methods for treating cns disorders | |
| JP2009504763A5 (enExample) | ||
| JP2010509366A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| JP2012506870A5 (enExample) | ||
| WO2018067520A2 (en) | Therapeutic agents and methods: |